Clinical Trial Update: Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study [Phase 1, Phase 2]

View source ↗

Summary

A prospective Phase 1/2 study evaluating the topical retinoid tazarotene 0.1% cream for Cutaneous T-Cell Lymphoma. The document provides trial status but does n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Tazarotene 0.1% Cream (tazarotene)

Snippet

Sponsor: McGill University | Conditions: Cutaneous T-Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN